AbbVie Inc. (ABBV)
| Market Cap | 510.41B +28.3% |
| Revenue (ttm) | 66.01B +10.7% |
| Net Income | 10.30B +333.1% |
| EPS | 5.81 +339.8% |
| Shares Out | 1.77B |
| PE Ratio | 49.73 |
| Forward PE | 18.36 |
| Dividend | $6.92 (2.40%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | 8,850,081 |
| Open | 290.38 |
| Previous Close | 294.89 |
| Day's Range | 286.14 - 294.86 |
| 52-Week Range | 190.75 - 298.74 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 305.58 (+5.8%) |
| Earnings Date | Oct 30, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $305.58, which is an increase of 5.80% from the latest price.
News
AbbVie price target raised to $330 from $280 at RBC Capital
RBC Capital raised the firm’s price target on AbbVie (ABBV) to $330 from $280 and keeps an Outperform rating on the shares. The company’s quarterly results validate a durable growth…
AbbVie price target raised to $325 from $279 at Leerink
Leerink analyst David Risinger raised the firm’s price target on AbbVie (ABBV) to $325 from $279 and keeps an Outperform rating on the shares. The firm notes the company’s commercial…
AbbVie price target raised to $325 from $279 at Leerink
Leerink raised the firm’s price target on AbbVie (ABBV) to $325 from $279 and keeps an Outperform rating on the shares. The firm notes the company’s commercial portfolio is delivering…
AbbVie signs global license agreement with Brise Pharmaceuticals in migraine
AbbVie (ABBV) provided an update on its exclusive license agreement with Brise Pharmaceuticals, which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsibl...
AbbVie price target raised to $325 from $290 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $325 from $290 and keeps an Overweight rating on the shares. AbbVie beat lowered Q3 expectations despite moderating Skyrizi…
AbbVie price target raised to $322 from $288 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $322 from $288 and keeps a Buy rating on the shares.
AbbVie price target raised to $338 from $290 at Canaccord
Canaccord raised the firm’s price target on AbbVie (ABBV) to $338 from $290 and keeps a Buy rating on the shares. The firm said Consistent solid performance in 3Q across…
AbbVie price target raised to $295 from $260 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on AbbVie (ABBV) to $295 from $260 and keeps a Neutral rating on the shares. The company reported another Skyrizi and…
AbbVie price target raised to $340 from $300 at Wells Fargo
Wells Fargo raised the firm’s price target on AbbVie (ABBV) to $340 from $300 and keeps an Overweight rating on the shares post the Q3 report. AbbVie’s outlook continues to…
AbbVie price target raised to $319 from $305 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $319 from $305 and keeps a Buy rating on the shares. The company reported a modest Q3 revenue beat and…
AbbVie price target raised to $346 from $310 at Morgan Stanley
Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $346 from $310 and keeps an Overweight rating on the shares. The company’s Q3 report was generally in line…
AbbVie price target raised to $295 from $275 at UBS
UBS analyst Michael Yee raised the firm’s price target on AbbVie (ABBV) to $295 from $275 and keeps a Neutral rating on the shares. The firm views the company’s Q3…
AbbVie Science Chief says interested in building out obesity assets
AbbVie (ABBV) Chief Scientific Officer Roopal Thakkar said on the company’s earnings call: “Yes, we continue to have interest to build out obesity assets. We are open to anything that…
AbbVie says too early to determine financial impact from 340B rebate pilot
10:00 EDT AbbVie (ABBV) says too early to determine financial impact from 340B rebate pilot
AbbVie sees Q4 adjusted EPS $3.83-$3.87, consensus $3.89
Sees Q4 revenue about $18.4B, consensus $18.3B.
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
09:35 EDT AbbVie (ABBV) sees FY26 adjusted gross margin ‘above 84% of sales’
AbbVie sees FY26 Skyrizi revenue $21.8B, FY26 Rinvoq revenue $10.3B
09:40 EDT AbbVie (ABBV) sees FY26 Skyrizi revenue $21.8B, FY26 Rinvoq revenue $10.3B
AbbVie says making ‘significant progress’ advancing pipeline
Says delivering “strong execution” across the business. Says Skyrizi, Rinvoq “exceeding expectations.” Comments taken from Q3 earnings conference call.
AbbVie sees FY26 revenue about $67.8B, consensus $67.62B
Prior view was FY26 revenue about $67.6B.
AbbVie Earnings Call Transcript: Q3 2026
Q3 revenue rose 10.5% operationally and adjusted EPS beat the midpoint, prompting higher FY guidance. Immunology and neuroscience led growth as pipeline milestones broadened longer-term prospects.
AbbVie Earnings release: Q3 2026
AbbVie released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
The pharmaceutical company boosted its profit outlook for the year, and raised its quarterly dividend as both third-quarter results and full-year guidance came in above expectations.
AbbVie Reports Third-Quarter 2026 Financial Results
Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable Im...
The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1 BOTOX® Cosmetic Day marks th...
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026 alon...